The Dangers of Synthetic Marijuana: Rising Cases of Poisoning and Death

Aug.09.2022
The Dangers of Synthetic Marijuana: Rising Cases of Poisoning and Death
Synthetic marijuana is dangerous and can cause severe reactions such as seizures, heart problems, and death. It is a growing problem globally.

On August 5, 2015, a man was preparing to smoke K2, a synthetic marijuana drug, on a street in East Harlem, New York City.


Synthetic cannabis, sold under catchy names such as AK-47, K2, Spice, and Scooby Snacks, is far from being a dreamy substance. Most synthetic cannabinoids are packaged in electronic cigarettes, juices, or foods, and sold as dried plant material that has been sprayed with solvents containing laboratory-made psychoactive substances such as acetone, preservatives, or other chemicals.


According to data from the ToxIC case registry, cases of synthetic cannabis poisoning were on the rise between 2010 and 2015, with over 42,000 reported toxic exposure cases during that period. However, Tracy Klein, the assistant director of the Cannabis Policy, Research and Outreach Center at Washington State University in Vancouver, suggests that these numbers may now be decreasing in states where recreational marijuana use is allowed.


She was the lead author of a study that found that in states where recreational marijuana had been legalized between 2016 and 2019, calls to poison control center related to synthetic marijuana decreased by over one-third.


These products are in powder form, which can be sprayed or added to substances that look exactly like natural marijuana. Therefore, in party situations, I can see how someone could accidentally use it," said Klein, who is also an associate professor at the WSU College of Nursing.


However, according to the Centers for Disease Control and Prevention in the United States, people may also use synthetic cannabinoids "in an attempt to avoid positive drug screenings for employment, drug abuse treatment programs, or the criminal justice system.


A fatal issue/problem.


Over the past decade, thousands of people have been rushed to the emergency room due to marijuana use. According to the Centers for Disease Control and Prevention, some individuals have even died, including a 17-year-old boy who reportedly experienced cardiac arrest after using K2/spice marijuana once.


Experts say it is impossible to know what synthetic cannabinoids are actually present in purchased products or what other substances might be present in solvents used to soak and dry plants.


In April 2018, 153 people in Illinois fell ill and four died after using synthetic marijuana that was laced with rat poison. Later that year, in New Haven, Connecticut, K2 marijuana caused 95 people to become ill within two days. They experienced symptoms such as nausea, vomiting, lethargy, and loss of consciousness.


Klein explained that these synthetic products are officially known as "synthetic cannabinoid receptor agonists," which are different from synthetic marijuana products that have medical uses.


They do not appear in standard drug tests," she said. "The body also does not recognize them in any way that has a positive effect.


This research was published on Tuesday in the Clinical Toxicology Journal, analyzing data from the National Poison Data System between 2016 and 2019. The researchers discovered that over these three years, there were 7600 calls relating to the use of synthetic cannabinoids. Approximately 65% of calls made to poison centers concerned situations requiring medical care, with 61 fatalities reported.


A study has revealed that over half of the calls made to poison control centers (56%) were from states with restrictions on marijuana policies. According to the study, nearly one-third (38.6%) of calls were made from states that allow drug use for medical purposes, while 5.5% were from "permissive" states where recreational use is legal.


The working principle of synthetic cannabinoids.


The Centers for Disease Control and Prevention (CDC) stated that synthetic cannabinoids were first developed in the 1980s for the purpose of studying how tetrahydrocannabinol (THC), the psychoactive ingredient in marijuana, affects the brain in producing high levels.


Klein stated, "A specific synthetic marijuana was designed by a pharmaceutical company as a potential pain relief medication. People discovered that it was so potent and had so many side effects that it was not being abused.


Today, synthetic materials are mainly produced overseas and transported to the United States. In fact, according to the Centers for Disease Control, the first shipment of "goods identified as containing synthetic cannabinoids was seized at the U.S. border in 2008.


This is not just a problem in the United States. It has become an international issue", stated Klein. He pointed out that, as of February 2022, data on illegal markets listed at least 320 different types of synthetic cannabinoids being sold.


She added, "These are only those that have been reported and identified.


Klein stated that, although different from natural cannabis, synthetic compounds do indeed act on the same cannabinoid receptors as THC. However, due to the manner in which they bind to brain receptors, their potency can increase up to 100 times.


Exposure could lead to a range of neurological reactions, from mild to severe, such as agitation and depression in the central nervous system, which could even result in coma. The Centers for Disease Control and Prevention highlight other symptoms including "fatigue, irritability, confusion, dizziness, lack of coordination, inability to concentrate, stroke and seizures.


The agency stated that symptoms of mental illness include "hallucinations, delusions, psychosis, violent behavior, and suicidal thoughts." "Other physical signs and symptoms include shortness of breath, tachycardia, hypertension, severe nausea and vomiting, chest pain and heart attack, rhabdomyolysis (damaged muscles rupturing), kidney failure, and death.


The Disease Prevention and Control Center stated that there is no antidote for synthetic cannabinoid toxicity, and the long-term effects are still unknown. Treatment options include intravenous fluids, oxygen therapy, airway protection, and medication for anxiety and aggression, but these treatments are only supportive measures.


Announcement:


This article has been compiled from third-party sources and is intended solely for industry knowledge and exchange.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the authenticity or accuracy of the article's content. The translation of this article is solely for industry communication and research.


Due to limitations in the level of translation ability, the translated article may not express the same meaning as the original. Please refer to the original text for accuracy.


2FIRSTS fully aligns with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and international issues and positions.


The copyright of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Global Nicotine-Pouch E-Commerce Group Haypp Shuts Sweden’s Snusnetto Over Age Verification as Identity Checks Become Industry Infrastructure for New Nicotine Products
Global Nicotine-Pouch E-Commerce Group Haypp Shuts Sweden’s Snusnetto Over Age Verification as Identity Checks Become Industry Infrastructure for New Nicotine Products
Sweden's Supreme Administrative Court has declined to hear an appeal over age verification for tobacco and nicotine products collected from parcel lockers, leaving in place a lower-court ruling that geo-located BankID verification is insufficient to securely verify the actual recipient. Haypp Group has stopped tobacco and nicotine sales through Snusnetto and is deploying a new system across its other Swedish e-commerce sites to verify the age of the person who actually opens the locker and receives the shipment. The change comes as age verification across next-generation nicotine products expands from purchase checks into retail, delivery and, for some e-cigarettes, device access itself.
Regulations
Oct.20
Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain Cigarette Volumes Fall 5.2% in August, BAT Drops 14.5%, JTI Gains Share; France Down 8.3% on Adjusted Basis
Spain's cigarette volumes declined 5.2% year over year in August 2026, according to government data cited by UBS and reported by Investing.com on October 7. British American Tobacco's volumes fell 14.5%, followed by Imperial Brands at 8.8%, Philip Morris International at 6.6% and Japan Tobacco at 4.6%. JTI was the only one of the four companies to gain cigarette market share, rising six basis points to 26.7%. In France, official customs data showed an unadjusted 3.7% decline in cigarette deliveries. Adjusting for the difference in delivery days produces a decline of approximately 8.3%, consistent with the UBS figure. The bank also estimated the earnings exposure of major tobacco companies to both markets.
Market
Oct.13
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
Philippines Mandates Safety Certification for Nicotine Pouches, Gives Industry 12 Months to Comply
The Philippines Department of Trade and Industry has placed nicotine pouches under mandatory product certification through Department Administrative Order No. 26-07, Series of 2026. Nicotine pouches must obtain a Philippine Standard, or PS, license before they can be manufactured, imported, packed, distributed or sold in the country. The regime requires testing for nicotine content, pH and water activity, while packaging must disclose nicotine strength, ingredients, allergens, batch information, the PS certification mark and prescribed health warnings. Existing market participants have a 12-month transition period to comply.
Regulations
Oct.12
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Special Report | From Oversupply to Supply Gaps: Global Tobacco Leaf Markets Diverge Ahead of 2027
Global tobacco leaf markets diverged sharply in 2026, with India cutting authorised FCV production amid oversupply while Malawi faced a supply shortfall. U.S. demand improved in some leaf categories, but growers in Brazil, Colombia, Tanzania and Zimbabwe faced pressure from prices, buyer access, costs and weather. With nicotine consumption patterns also shifting, 2027 will test whether supply, demand and grower profitability can move back toward balance.
Oct.26
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
Nov.10
EU TPD Revision May Slip to 2027: Parliament Backs Wider Nicotine Rules by 447 Votes as Commission Impact Assessment Reportedly Receives Negative Opinion
EU TPD Revision May Slip to 2027: Parliament Backs Wider Nicotine Rules by 447 Votes as Commission Impact Assessment Reportedly Receives Negative Opinion
On Nov 12, 2026, the European Parliament adopted a resolution on implementing Europe’s Beating Cancer Plan by 447 votes to 66, with 91 abstentions, urging the European Commission to speed up revisions to the Tobacco Products Directive (TPD) and Tobacco Advertising Directive (TAD). Parliament called for broader regulation of e-cigarettes, heated tobacco, nicotine pouches and other emerging nicotine products, proposing measures on packaging, health warnings, flavors, ingredient reporting, online age verification, digital marketing and premarket health impact assessments. EUNews and others reported that the Commission’s Regulatory Scrutiny Board (RSB) issued a negative opinion on the revisions’ impact assessment on Nov 9. The Commission had scheduled the initiative for December 2026, but the reported setback could push the legislative proposal into 2027. No revised official timetable has been announced, and Parliament’s resolution does not amend existing EU law.
Regulations
Nov.19